Literature DB >> 19041240

Lead identification to generate 3-cyanoquinoline inhibitors of insulin-like growth factor receptor (IGF-1R) for potential use in cancer treatment.

Lori M Miller1, Scott C Mayer, Dan M Berger, Diane H Boschelli, Frank Boschelli, Li Di, Xuemei Du, Minu Dutia, Middleton B Floyd, Mark Johnson, Cynthia Hess Kenny, Girija Krishnamurthy, Franklin Moy, Susan Petusky, Diane Tkach, Nancy Torres, Biqi Wu, Weixin Xu.   

Abstract

Insulin-like growth factor receptor (IGF-1R) is a growth factor receptor tyrosine kinase that acts as a critical mediator of cell proliferation and survival. Inhibitors of this receptor are believed to provide a new target in cancer therapy. We previously reported an isoquinolinedione series of IGF-1R inhibitors. Now we have identified a series of 3-cyanoquinoline compounds that are low nanomolar inhibitors of IGF-1R. The strategies, synthesis, and SAR behind the cyanoquinoline scaffold will be discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19041240     DOI: 10.1016/j.bmcl.2008.11.037

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  9 in total

1.  Synthesis of aryl-heteroaryl ureas (AHUs) based on 4-aminoquinoline and their evaluation against the insulin-like growth factor receptor (IGF-1R).

Authors:  William Engen; Terrence E O'Brien; Brendan Kelly; Jacinda Do; Liezel Rillera; Lance K Stapleton; Jack F Youngren; Marc O Anderson
Journal:  Bioorg Med Chem       Date:  2010-06-25       Impact factor: 3.641

2.  Identifying three-dimensional structures of autophosphorylation complexes in crystals of protein kinases.

Authors:  Qifang Xu; Kimberly L Malecka; Lauren Fink; E Joseph Jordan; Erin Duffy; Samuel Kolander; Jeffrey R Peterson; Roland L Dunbrack
Journal:  Sci Signal       Date:  2015-12-01       Impact factor: 8.192

3.  Serine phosphorylation of the insulin-like growth factor I (IGF-1) receptor C-terminal tail restrains kinase activity and cell growth.

Authors:  Geraldine M Kelly; Deirdre A Buckley; Patrick A Kiely; David R Adams; Rosemary O'Connor
Journal:  J Biol Chem       Date:  2012-06-08       Impact factor: 5.157

Review 4.  Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach.

Authors:  Rongshi Li; Alan Pourpak; Stephan W Morris
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

5.  Quinoline: A versatile heterocyclic.

Authors:  Akranth Marella; Om Prakash Tanwar; Rikta Saha; Mohammad Rahmat Ali; Sandeep Srivastava; Mymoona Akhter; Mohammad Shaquiquzzaman; Mohammad Mumtaz Alam
Journal:  Saudi Pharm J       Date:  2012-03-29       Impact factor: 4.330

6.  A highly selective dual insulin receptor (IR)/insulin-like growth factor 1 receptor (IGF-1R) inhibitor derived from an extracellular signal-regulated kinase (ERK) inhibitor.

Authors:  Theonie Anastassiadis; Krisna C Duong-Ly; Sean W Deacon; Alec Lafontant; Haiching Ma; Karthik Devarajan; Roland L Dunbrack; Jinhua Wu; Jeffrey R Peterson
Journal:  J Biol Chem       Date:  2013-08-09       Impact factor: 5.157

7.  How IGF-1 activates its receptor.

Authors:  Jennifer M Kavran; Jacqueline M McCabe; Patrick O Byrne; Mary Katherine Connacher; Zhihong Wang; Alexander Ramek; Sarvenaz Sarabipour; Yibing Shan; David E Shaw; Kalina Hristova; Philip A Cole; Daniel J Leahy
Journal:  Elife       Date:  2014-09-25       Impact factor: 8.140

8.  Virtual screening of specific insulin-like growth factor 1 receptor (IGF1R) inhibitors from the National Cancer Institute (NCI) molecular database.

Authors:  Cong Fan; Yan-Xin Huang; Yong-Li Bao; Lu-Guo Sun; Yin Wu; Chun-Lei Yu; Yu Zhang; Zhen-Bo Song; Li-Hua Zheng; Ying Sun; Guan-Nan Wang; Yu-Xin Li
Journal:  Int J Mol Sci       Date:  2012-12-14       Impact factor: 5.923

9.  Antiproliferative and Carbonic Anhydrase II Inhibitory Potential of Chemical Constituents from Lycium shawii and Aloe vera: Evidence from In Silico Target Fishing and In Vitro Testing.

Authors:  Najeeb Ur Rehman; Sobia Ahsan Halim; Majid Khan; Hidayat Hussain; Husain Yar Khan; Ajmal Khan; Ghulam Abbas; Kashif Rafiq; Ahmed Al-Harrasi
Journal:  Pharmaceuticals (Basel)       Date:  2020-05-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.